Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.currproblcancer.2015.07.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk assessment of venetoclax-associated adverse events: a meta-analysis approach.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
Introduction: Venetoclax, an oral B-cell lymphoma-2 (BCL-2) inhibitor, shows promise in cancer treatment but has an unclear safety profile. This meta-analysis evaluates the safety of venetoclax, focusing on adverse events.
Methods: Data from PubMed, Embase, Cochrane databases, and ClinicalTrials.
Prevention and Management of Infectious Complications in Pediatric Patients With Cancer: A Survey Assessment of Current Practices Across Children's Oncology Group Institutions.
Pediatr Blood Cancer
March 2025
Department of Pediatrics, Vanderbilt University Medical Center and the Monroe Carell Jr. Children's Hospital at Vanderbilt and the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
Introduction: While clinical practice guidelines (CPGs) for pediatric oncology infection prophylaxis and management exist, few data describe actual management occurring at pediatric oncology centers.
Methods: An electronic survey querying infection management practices in nontransplant pediatric oncology patients was iteratively created by the Children's Oncology Group (COG) Cancer Control and Supportive Care Infectious Diseases Subcommittee and sent to leaders at all COG institutions, limiting each site to one response to represent their institution.
Results: The response rate was 57% (129/227 institutions).
Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine.
Cells
December 2024
Department of Nursing, College of Nursing and Health Sciences, Jazan University, Jazan 45142, Saudi Arabia.
Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody-drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement.
View Article and Find Full Text PDFEvaluation of the consumption pattern and efficacy of Linezolid in COVID-19 hospitalized patients in a hospital in Tehran-Iran.
Daru
January 2025
Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Background: The inappropriate use of antibiotics increases the costs of treatment, antibiotic resistance, increased disease length and duration of hospital stay.
Objectives: The aim of this study was investigating the pattern of use and effectiveness of the Linezolid in COVID-19 hospitalized patients.
Methods: In this retrospective cross-sectional analytical study was carried out from February 2020 (from the beginning of the pandemic in Iran) to the end of September 2020, 32 COVID-19 patients that used Linezolid were included.
Impact of diagnostic stewardship on catheter-associated urinary tract infections and patient outcomes.
Infect Control Hosp Epidemiol
December 2024
Rush University Medical Center, ChicagoIL, USA.
Article Synopsis
- The study aimed to evaluate a computerized clinical decision support tool for urine cultures in patients with indwelling urinary catheters, focusing on improving diagnostic appropriateness and reducing unnecessary tests.
- The intervention was associated with a significant reduction in the number of urine cultures performed, but it did not lead to a noticeable decrease in catheter-associated urinary tract infection (CAUTI) rates.
- Adverse outcomes from averted cultures were minimal, suggesting that diagnostic stewardship can be safely integrated into practices to limit unnecessary testing while maintaining patient safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!